Merck Adds to Biotech Center

Merck Serono, a unit of Merck KGaA, says it will invest about €300 million ($390 million) to expand production of cetuximab at its Merck Serono Biotech Center (MSBC) at Corsier-sur-Vevey, Switzerland. The expansion is expected to be completed in 2012, pending inspection by worldwide health authorities. Cetuximab is a monoclonal antibody used in the treatment of colorectal, head, and neck cancers. The expansion includes adding two dedicated production suites with 120,000 liters of bioreactor capacity, a wastewater treatment station, and a logistic center to...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers